The global GP Vaccination market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global GP Vaccination market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global GP Vaccination market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global GP Vaccination market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global GP Vaccination market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global GP Vaccination market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for GP Vaccination
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global GP Vaccination market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Moderna, CanSino Biologicals, Inovio Pharmaceuticals, Shenzhen Geno-Immune Medical Institute, GlaxoSmithKine, Pfizer, 闯辞丑苍蝉辞苍锛咼辞丑苍蝉辞苍, Heat Biologics, Sanofi, Takis Biotech, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
GP Vaccination market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
DNA
Non-replicating Viral Vector
Protein Subunit
RNA
Others
麻豆原创 segment by Application
Adults
Children
Major players covered
Moderna
CanSino Biologicals
Inovio Pharmaceuticals
Shenzhen Geno-Immune Medical Institute
GlaxoSmithKine
Pfizer
闯辞丑苍蝉辞苍锛咼辞丑苍蝉辞苍
Heat Biologics
Sanofi
Takis Biotech
Zydus Cadila
Codagenix
GeoVax
Bravovax
Altimmune
Vaxart
Clover Biopharmaceuticals
ImmunoPrecise
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe GP Vaccination product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of GP Vaccination, with price, sales quantity, revenue, and global market share of GP Vaccination from 2020 to 2025.
Chapter 3, the GP Vaccination competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the GP Vaccination breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and GP Vaccination market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of GP Vaccination.
Chapter 14 and 15, to describe GP Vaccination sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global GP Vaccination Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 DNA
1.3.3 Non-replicating Viral Vector
1.3.4 Protein Subunit
1.3.5 RNA
1.3.6 Others
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global GP Vaccination Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Adults
1.4.3 Children
1.5 Global GP Vaccination 麻豆原创 Size & Forecast
1.5.1 Global GP Vaccination Consumption Value (2020 & 2024 & 2031)
1.5.2 Global GP Vaccination Sales Quantity (2020-2031)
1.5.3 Global GP Vaccination Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Moderna
2.1.1 Moderna Details
2.1.2 Moderna Major Business
2.1.3 Moderna GP Vaccination Product and Services
2.1.4 Moderna GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Moderna Recent Developments/Updates
2.2 CanSino Biologicals
2.2.1 CanSino Biologicals Details
2.2.2 CanSino Biologicals Major Business
2.2.3 CanSino Biologicals GP Vaccination Product and Services
2.2.4 CanSino Biologicals GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 CanSino Biologicals Recent Developments/Updates
2.3 Inovio Pharmaceuticals
2.3.1 Inovio Pharmaceuticals Details
2.3.2 Inovio Pharmaceuticals Major Business
2.3.3 Inovio Pharmaceuticals GP Vaccination Product and Services
2.3.4 Inovio Pharmaceuticals GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Inovio Pharmaceuticals Recent Developments/Updates
2.4 Shenzhen Geno-Immune Medical Institute
2.4.1 Shenzhen Geno-Immune Medical Institute Details
2.4.2 Shenzhen Geno-Immune Medical Institute Major Business
2.4.3 Shenzhen Geno-Immune Medical Institute GP Vaccination Product and Services
2.4.4 Shenzhen Geno-Immune Medical Institute GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Shenzhen Geno-Immune Medical Institute Recent Developments/Updates
2.5 GlaxoSmithKine
2.5.1 GlaxoSmithKine Details
2.5.2 GlaxoSmithKine Major Business
2.5.3 GlaxoSmithKine GP Vaccination Product and Services
2.5.4 GlaxoSmithKine GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 GlaxoSmithKine Recent Developments/Updates
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer GP Vaccination Product and Services
2.6.4 Pfizer GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Pfizer Recent Developments/Updates
2.7 闯辞丑苍蝉辞苍锛咼辞丑苍蝉辞苍
2.7.1 闯辞丑苍蝉辞苍锛咼辞丑苍蝉辞苍 Details
2.7.2 闯辞丑苍蝉辞苍锛咼辞丑苍蝉辞苍 Major Business
2.7.3 闯辞丑苍蝉辞苍锛咼辞丑苍蝉辞苍 GP Vaccination Product and Services
2.7.4 闯辞丑苍蝉辞苍锛咼辞丑苍蝉辞苍 GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 闯辞丑苍蝉辞苍锛咼辞丑苍蝉辞苍 Recent Developments/Updates
2.8 Heat Biologics
2.8.1 Heat Biologics Details
2.8.2 Heat Biologics Major Business
2.8.3 Heat Biologics GP Vaccination Product and Services
2.8.4 Heat Biologics GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Heat Biologics Recent Developments/Updates
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi GP Vaccination Product and Services
2.9.4 Sanofi GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Sanofi Recent Developments/Updates
2.10 Takis Biotech
2.10.1 Takis Biotech Details
2.10.2 Takis Biotech Major Business
2.10.3 Takis Biotech GP Vaccination Product and Services
2.10.4 Takis Biotech GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Takis Biotech Recent Developments/Updates
2.11 Zydus Cadila
2.11.1 Zydus Cadila Details
2.11.2 Zydus Cadila Major Business
2.11.3 Zydus Cadila GP Vaccination Product and Services
2.11.4 Zydus Cadila GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Zydus Cadila Recent Developments/Updates
2.12 Codagenix
2.12.1 Codagenix Details
2.12.2 Codagenix Major Business
2.12.3 Codagenix GP Vaccination Product and Services
2.12.4 Codagenix GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Codagenix Recent Developments/Updates
2.13 GeoVax
2.13.1 GeoVax Details
2.13.2 GeoVax Major Business
2.13.3 GeoVax GP Vaccination Product and Services
2.13.4 GeoVax GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 GeoVax Recent Developments/Updates
2.14 Bravovax
2.14.1 Bravovax Details
2.14.2 Bravovax Major Business
2.14.3 Bravovax GP Vaccination Product and Services
2.14.4 Bravovax GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Bravovax Recent Developments/Updates
2.15 Altimmune
2.15.1 Altimmune Details
2.15.2 Altimmune Major Business
2.15.3 Altimmune GP Vaccination Product and Services
2.15.4 Altimmune GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Altimmune Recent Developments/Updates
2.16 Vaxart
2.16.1 Vaxart Details
2.16.2 Vaxart Major Business
2.16.3 Vaxart GP Vaccination Product and Services
2.16.4 Vaxart GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Vaxart Recent Developments/Updates
2.17 Clover Biopharmaceuticals
2.17.1 Clover Biopharmaceuticals Details
2.17.2 Clover Biopharmaceuticals Major Business
2.17.3 Clover Biopharmaceuticals GP Vaccination Product and Services
2.17.4 Clover Biopharmaceuticals GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Clover Biopharmaceuticals Recent Developments/Updates
2.18 ImmunoPrecise
2.18.1 ImmunoPrecise Details
2.18.2 ImmunoPrecise Major Business
2.18.3 ImmunoPrecise GP Vaccination Product and Services
2.18.4 ImmunoPrecise GP Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 ImmunoPrecise Recent Developments/Updates
3 Competitive Environment: GP Vaccination by Manufacturer
3.1 Global GP Vaccination Sales Quantity by Manufacturer (2020-2025)
3.2 Global GP Vaccination Revenue by Manufacturer (2020-2025)
3.3 Global GP Vaccination Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of GP Vaccination by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 GP Vaccination Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 GP Vaccination Manufacturer 麻豆原创 Share in 2024
3.5 GP Vaccination 麻豆原创: Overall Company Footprint Analysis
3.5.1 GP Vaccination 麻豆原创: Region Footprint
3.5.2 GP Vaccination 麻豆原创: Company Product Type Footprint
3.5.3 GP Vaccination 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global GP Vaccination 麻豆原创 Size by Region
4.1.1 Global GP Vaccination Sales Quantity by Region (2020-2031)
4.1.2 Global GP Vaccination Consumption Value by Region (2020-2031)
4.1.3 Global GP Vaccination Average Price by Region (2020-2031)
4.2 North America GP Vaccination Consumption Value (2020-2031)
4.3 Europe GP Vaccination Consumption Value (2020-2031)
4.4 Asia-Pacific GP Vaccination Consumption Value (2020-2031)
4.5 South America GP Vaccination Consumption Value (2020-2031)
4.6 Middle East & Africa GP Vaccination Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global GP Vaccination Sales Quantity by Type (2020-2031)
5.2 Global GP Vaccination Consumption Value by Type (2020-2031)
5.3 Global GP Vaccination Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global GP Vaccination Sales Quantity by Application (2020-2031)
6.2 Global GP Vaccination Consumption Value by Application (2020-2031)
6.3 Global GP Vaccination Average Price by Application (2020-2031)
7 North America
7.1 North America GP Vaccination Sales Quantity by Type (2020-2031)
7.2 North America GP Vaccination Sales Quantity by Application (2020-2031)
7.3 North America GP Vaccination 麻豆原创 Size by Country
7.3.1 North America GP Vaccination Sales Quantity by Country (2020-2031)
7.3.2 North America GP Vaccination Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe GP Vaccination Sales Quantity by Type (2020-2031)
8.2 Europe GP Vaccination Sales Quantity by Application (2020-2031)
8.3 Europe GP Vaccination 麻豆原创 Size by Country
8.3.1 Europe GP Vaccination Sales Quantity by Country (2020-2031)
8.3.2 Europe GP Vaccination Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific GP Vaccination Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific GP Vaccination Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific GP Vaccination 麻豆原创 Size by Region
9.3.1 Asia-Pacific GP Vaccination Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific GP Vaccination Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America GP Vaccination Sales Quantity by Type (2020-2031)
10.2 South America GP Vaccination Sales Quantity by Application (2020-2031)
10.3 South America GP Vaccination 麻豆原创 Size by Country
10.3.1 South America GP Vaccination Sales Quantity by Country (2020-2031)
10.3.2 South America GP Vaccination Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa GP Vaccination Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa GP Vaccination Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa GP Vaccination 麻豆原创 Size by Country
11.3.1 Middle East & Africa GP Vaccination Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa GP Vaccination Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 GP Vaccination 麻豆原创 Drivers
12.2 GP Vaccination 麻豆原创 Restraints
12.3 GP Vaccination Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of GP Vaccination and Key Manufacturers
13.2 Manufacturing Costs Percentage of GP Vaccination
13.3 GP Vaccination Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 GP Vaccination Typical Distributors
14.3 GP Vaccination Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Moderna
CanSino Biologicals
Inovio Pharmaceuticals
Shenzhen Geno-Immune Medical Institute
GlaxoSmithKine
Pfizer
闯辞丑苍蝉辞苍锛咼辞丑苍蝉辞苍
Heat Biologics
Sanofi
Takis Biotech
Zydus Cadila
Codagenix
GeoVax
Bravovax
Altimmune
Vaxart
Clover Biopharmaceuticals
ImmunoPrecise
听
听
*If Applicable.
